Scrum Master
About the job
- SAFe Certified Scrum Master (SSM), SAFe Advanced Scrum Master (SASM), or SAFe Release Train Engineer (RTE) certification.
- Hands-on experience with Agile Portfolio Management and Agile Governance.
- Experience as a Scrum Master in Agile and SAFe environments.
- Deep understanding of SAFe principles, Agile Release Trains (ARTs), Lean-Agile frameworks, and Agile coaching.
- Hands-on experience with SAFe Agile ceremonies, PI Planning, Scrum of Scrums, Inspect & Adapt, and Iteration execution.
- Strong knowledge of Agile methodologies (Scrum, Kanban, XP, SAFe) and enterprise Agile transformations.
- Proficiency in Agile project management tools (JIRA, Rally, Azure DevOps, Confluence, Miro).
- Experience with Lean Portfolio Management (LPM), Lean-Agile metrics, and flow-based work management.
- Ability to coach, mentor, and empower Agile teams, fostering collaboration, servant leadership, and high performance.
- Strong communication and stakeholder management skills, ensuring alignment across business and technical teams.
- Understanding of DevOps, CI/CD, Test Automation, and Agile Quality Assurance.
- Proven ability to resolve conflicts, remove blockers, and optimize team performance.
- A doctorate degree and 3–5+ years of experience in Computer Science, IT, or a related field; or a master’s degree and 6–8+ years of experience in Computer Science, IT, or a related field; or a bachelor’s degree and 8–10+ years of experience in Computer Science, IT, or a related field.
- Excellent analytical and troubleshooting skills.
- Strong verbal and written communication skills.
- Ability to work effectively with global, virtual teams.
- High degree of initiative and self-motivation.
- Ability to manage multiple priorities successfully.
- Ability to learn quickly, be organized, and detail-oriented.
- Strong presentation and public speaking skills.
- Act as a Scrum Master within a Scaled Agile (SAFe) environment, facilitating Agile ceremonies such as PI Planning, Scrum of Scrums, Sprint Planning, Daily Stand-ups, Sprint Reviews, and Inspect & Adapt sessions.
- Guide and support Agile teams, Product Owners, and stakeholders, fostering self-organization, cross-team collaboration, and high-performance delivery.
- Coach Agile Release Train (ART) teams on SAFe best practices, Lean-Agile principles, and Agile mindset adoption.
- Facilitate Program Increment (PI) Planning and ART synchronization, ensuring clear dependencies, objectives, and risk mitigation strategies.
- Remove organizational and technical impediments, enabling teams to deliver value faster and with higher quality.
- Promote continuous improvement and relentless execution, guiding teams in identifying and implementing retrospective action items.
- Assist Product Owners and Business Owners in effective backlog management, prioritization, and value-driven decision-making.
- Foster an environment of transparency, psychological safety, and accountability, enabling trust and continuous learning.
- Drive SAFe Lean Portfolio Management practices, ensuring alignment between strategic initiatives and Agile execution.
- Enable Agile metrics tracking and reporting, leveraging KPIs such as Velocity, Flow Efficiency, Lead Time, and Predictability to measure team progress.
- Collaborate with Release Train Engineers (RTEs), Solution Architects, and DevOps teams to optimize delivery pipelines and Agile execution.
- Promote DevOps and CI/CD adoption, fostering a culture of Lean-Agile technical excellence and innovation.
- Stay updated with SAFe and Agile industry trends, continuously improving Agile methodologies, frameworks, and tools.
- Domain experience with the Biotech/Pharma industry.
- Additional certifications in Certified Scrum Master (CSM), Professional Scrum Master (PSM), or SAFe Agilist (SA).
- Experience in leading SAFe implementations, Agile transformations, and enterprise Agile coaching.
- Knowledge of Value Stream Mapping, Lean Thinking, and OKR-based goal setting.
About the company
Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
- Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
- Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.
What critics are saying
- Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
- MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
- Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.
What makes Amgen unique
- It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
- Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
- Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.
Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.